TWD 70.8
(0.28%)
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2023 | 17.89 Million TWD | 118.36% |
2022 | 8.19 Million TWD | 40.53% |
2021 | 5.83 Million TWD | 149.44% |
2020 | 2.33 Million TWD | -81.27% |
2019 | 12.48 Million TWD | 0.0% |
Year | Gross Profit | Gross Profit Growth |
---|---|---|
2024 Q2 | 3.08 Million TWD | 206.46% |
2024 Q1 | 1 Million TWD | -76.31% |
2023 Q3 | 4.24 Million TWD | -36.44% |
2023 FY | 17.89 Million TWD | 118.36% |
2023 Q2 | 6.68 Million TWD | 145.14% |
2023 Q1 | 2.72 Million TWD | 79.99% |
2023 Q4 | 4.24 Million TWD | 0.0% |
2022 FY | 8.19 Million TWD | 40.53% |
2022 Q4 | 1.51 Million TWD | 0.0% |
2021 FY | 5.83 Million TWD | 149.44% |
2020 FY | 2.33 Million TWD | 0.0% |
Name | Gross Profit | Gross Profit Difference |
---|---|---|
Apex Biotechnology Corp. | 531.11 Million TWD | 96.63% |
Sinphar Pharmaceutical Co.,Ltd. | 1.09 Billion TWD | 98.36% |
Panion & Bf Biotech Inc. | 912.56 Million TWD | 98.039% |
Chunghwa Chemical Synthesis & Biotech Co., Ltd. | 757.3 Million TWD | 97.637% |
GenMont Biotech Incorporation | 177.33 Million TWD | 89.908% |
Abnova (Taiwan) Corporation | 173.91 Million TWD | 89.709% |
Adimmune Corporation | 410.93 Million TWD | 95.645% |
Tanvex BioPharma, Inc. | 59.7 Million TWD | 70.022% |
Polaris Group | -137.9 Million TWD | 112.978% |
Energenesis Biomedical CO.,LTD. | 5.22 Million TWD | -242.395% |
PELL Bio-Med Technology Co. Ltd. | -26.14 Million TWD | 168.466% |